| Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease (NCT05085275) | USRC Kidney Research | 2022-03-30 |
| Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (NCT04922645) | USRC Kidney Research | 2021-06-29 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis (NCT04766398) | Kyowa Kirin Co., Ltd. | 2021-03-15 |
| Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis (NCT04771780) | Kyowa Kirin Co., Ltd. | 2021-03-15 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis (NCT04767581) | Kyowa Kirin Co., Ltd. | 2021-03-08 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis (NCT04766385) | Kyowa Kirin Co., Ltd. | 2021-03-03 |
| Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease (NCT04579315) | Bo Feldt-Rasmussen | 2020-11-30 |
| Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia (NCT04549597) | Ardelyx | 2020-11-20 |
| To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder (NCT04440696) | Grand Life Science (Liaoning) Co., Ltd. | 2020-10-21 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients (NCT04551300) | Shanghai Alebund Pharmaceuticals Limited | 2020-10-13 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (NCT04278404) | Duke University | 2020-03-05 |
| Rate of Termination of Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electrolytes (NCT04256369) | King Faisal Specialist Hospital & Research Center | 2020-02-02 |
| Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients (NCT04046263) | University of Colorado, Denver | 2020-02-01 |
| Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) (NCT03573089) | The University of Queensland | 2019-12-10 |
| Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients (NCT03861247) | Chen Jing | 2019-11-29 |
| Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia (NCT04789876) | Taylor's University | 2019-11-01 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis (NCT03984760) | Panion & BF Biotech Inc. | 2019-06-19 |
| A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP (NCT03988920) | Ardelyx | 2019-06-15 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis (NCT04456803) | Sinomune Pharmaceutical Co., Ltd | 2019-05-24 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients (NCT03864445) | Kyowa Kirin Co., Ltd. | 2019-04-29 |
| Dose-finding Study of KHK7791 in Hyperphosphatemia Patients (NCT03864458) | Kyowa Kirin Co., Ltd. | 2019-04-15 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy (NCT03824587) | Ardelyx | 2019-02-28 |
| Phosphate Microvascular Study (NCT03594539) | Veterans Medical Research Foundation | 2019-01-01 |
| A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD (NCT03831607) | Kyowa Kirin Co., Ltd. | 2018-12-27 |
| PA21 Safety and Efficacy in Adult Chinese Subjects (NCT03644264) | Vifor Fresenius Medical Care Renal Pharma | 2018-08-31 |
| Behavioral Management of Phosphorus in Hemodialysis Patients (NCT02940743) | NYU Langone Health | 2018-04-23 |
| Velphoro and Impact on the Oral Cavity and Gut Microbiome (NCT03409757) | RWTH Aachen University | 2018-02-28 |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis (NCT03427125) | Ardelyx | 2018-01-08 |
| Low-Phosphate Diet and Fibroblast Growth Factor-23 Level (NCT03367338) | Wan-Chuan Tsai | 2018-01-03 |
| DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis (NCT03305471) | Daiichi Sankyo | 2017-08-17 |
| Hyperphosphatemia in Children With Chronic Kidney Disease (NCT03202407) | Assiut University | 2017-08-01 |
| Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China (NCT03001011) | Sanofi | 2017-06-07 |
| The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis (NCT03163576) | Assiut University | 2017-06-01 |
| Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients (NCT03079869) | Kaiser Permanente | 2017-05-01 |
| Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis (NCT03256838) | Panion & BF Biotech Inc. | 2017-04-12 |
| Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices (NCT03146923) | University College Cork | 2017-03-06 |
| A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis (NCT02965053) | Chugai Pharmaceutical | 2016-12-01 |
| Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia (NCT02836184) | Jiujiang No.1 People's Hospital | 2016-07-01 |
| A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia (NCT02688764) | Vifor Fresenius Medical Care Renal Pharma | 2016-05-26 |
| Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients (NCT02684643) | Huashan Hospital | 2016-01-01 |
| Efficacy of Dietary Education and Education on Phosphate Binder Use in Hemodialysis Patients (NCT02755961) | Ajou University School of Medicine | 2015-07-01 |
| A Study of Ferric Citrate to Improve Inflammation and Lipid Levels (NCT02661295) | Winthrop University Hospital | 2015-07-01 |
| A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis (NCT02469467) | KDL Inc. | 2015-06-01 |
| Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D (NCT02492620) | Denver Nephrologists, P.C. | 2015-03-01 |
| Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia (NCT02237534) | Osaka University | 2014-09-01 |
| Dose-finding Study of MCI-196 (NCT01814904) | Tanabe Pharma Corporation | 2014-04-01 |
| Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules (NCT02027662) | Fresenius Medical Care Deutschland GmbH | 2014-01-01 |
| Fosrenol Post-marketing Surveillance in Japan (NCT01955876) | Bayer | 2013-10-10 |
| Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects (NCT01976572) | Tanabe Pharma Corporation | 2013-10-01 |
| Safety and Tolerability Study of MCI-196 (NCT01818687) | Tanabe Pharma Corporation | 2013-08-01 |
| Long-term Extension Study of MCI-196 (NCT01814917) | Tanabe Pharma Corporation | 2013-08-01 |
| A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia (NCT01850641) | Kissei Pharmaceutical Co., Ltd. | 2013-04-29 |
| A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia (NCT01850602) | Kissei Pharmaceutical Co., Ltd. | 2013-04-23 |
| Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (NCT01742611) | Astellas Pharma Inc | 2013-03-01 |
| A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis (NCT01696279) | Shire | 2013-02-15 |
| Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol (NCT01725113) | Winthrop University Hospital | 2012-11-01 |
| A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (NCT01742585) | Astellas Pharma Inc | 2012-10-01 |
| A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis (NCT01554982) | Keryx Biopharmaceuticals | 2012-08-01 |
| The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients (NCT01854437) | Shiraz University of Medical Sciences | 2012-06-01 |
| An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease (NCT01574326) | Genzyme, a Sanofi Company | 2012-05-01 |
| Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate (NCT00364000) | Romanian Society of Nephrology | 2012-01-01 |
| Effect of Restriction of Foods Containing Phosphorus Additives (NCT01965379) | Faculdade de Ciências Médicas da Santa Casa de São Paulo | 2012-01-01 |
| Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study (NCT01578200) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2011-12-24 |
| PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum (NCT01319578) | Denver Nephrologists, P.C. | 2011-07-01 |
| The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan (NCT01238588) | Brigham and Women's Hospital | 2011-06-10 |
| The Effect of Systemic Dietary Instruction on Management of Plasma Phosphorus Levels in Peritoneal Dialysis (PD) Patients (NCT01329497) | Shanghai Jiao Tong University School of Medicine | 2011-01-01 |
| A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis (NCT01191255) | Keryx Biopharmaceuticals | 2010-10-01 |
| Long-term Study in Chronic Kidney Disease (Extension From Study 14817) (NCT01187628) | Bayer | 2010-09-01 |
| The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient (NCT01245517) | Taipei Medical University WanFang Hospital | 2010-09-01 |
| Phosphate Kinetic Modeling 2 (NCT01252771) | Fresenius Medical Care North America | 2010-09-01 |
| Nicotinamide in Hemodialysis Patients With Hyperphosphatemia (NCT01200784) | Medice Arzneimittel Pütter GmbH & Co KG | 2010-08-01 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease (NCT01503736) | Panion & BF Biotech Inc. | 2010-06-01 |
| Study in Chronic Kidney Disease (CKD) Not on Dialysis (NCT01110629) | Bayer | 2010-06-01 |
| A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (NCT01074125) | Keryx Biopharmaceuticals | 2010-05-01 |
| Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients (NCT01069692) | Novartis | 2010-02-01 |
| Bioequivalence Study of BAY77-1931 Granule (NCT01053676) | Bayer | 2010-01-01 |
| Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (NCT00967993) | Keryx Biopharmaceuticals | 2010-01-01 |
| Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia (NCT01057108) | Denver Nephrologists, P.C. | 2010-01-01 |
| A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia (NCT01039428) | KDL Inc. | 2009-12-01 |
| Hypophosphatemic Rickets in Norway (NCT01057186) | Haukeland University Hospital | 2009-12-01 |
| Phosphate Kinetic Modeling (NCT01003223) | Fresenius Medical Care North America | 2009-10-01 |
| Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis (NCT00892749) | Astellas Pharma Inc | 2009-05-01 |
| Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (NCT01419327) | Bayer | 2009-03-23 |
| An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients (NCT00834301) | Nephrian | 2009-01-01 |
| Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD) (NCT00837655) | Karolinska Institutet | 2009-01-01 |
| A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis (NCT00833768) | Genzyme, a Sanofi Company | 2009-01-01 |
| Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia (NCT00772382) | Tanabe Pharma Corporation | 2008-12-01 |
| Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers (NCT00742820) | Fresenius Medical Care North America | 2008-08-01 |
| A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) (NCT00648167) | Keryx Biopharmaceuticals | 2008-03-01 |
| Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients (NCT00660530) | University of Illinois at Chicago | 2008-01-01 |
| A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (NCT00542386) | Tanabe Pharma Corporation | 2007-12-01 |
| A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia (NCT00542815) | Tanabe Pharma Corporation | 2007-11-01 |
| A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis (NCT00505037) | Astellas Pharma Inc | 2007-10-01 |
| A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia (NCT00506441) | Tanabe Pharma Corporation | 2007-09-01 |
| A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia (NCT00416520) | Tanabe Pharma Corporation | 2007-06-01 |
| Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients (NCT01755078) | Chugai Pharma Taiwan | 2007-06-01 |
| A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia (NCT00451295) | Tanabe Pharma Corporation | 2007-05-01 |
| Phosphorus Improvement Pilot Study (NCT00583570) | MetroHealth Medical Center | 2007-05-01 |
| Long-term Effect of Lanthanum Carbonate on Bone (NCT00557323) | Shire | 2007-03-15 |
| The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients (NCT00508885) | Washington University School of Medicine | 2006-10-01 |